“…In this study, CPL caused 36.44% and 66.66% of the growth inhibition of Ehrlich ascites carcinoma (EAC) when intraperitoneally administered at doses of 3 and 6 mg/kg/day, respectively. Compared to CPL, TCSL (28% and 72% at doses of 1 and 2 mg/kg/day), TDSL (7%, 50.2% and 60.3% at doses of 0.75, 1.5 and 3 mg/kg/day) and MCL (28%, 45% and 75% at doses of 1.2, 2.0 and 2.8 mg/kg/day) exerted stronger in vivo antiproliferative activity against EAC cells, though TDSL and MCL are more toxic than CPL [ 24 , 25 , 30 ]. Both TDSL and CPL agglutinated EAC cells, but morphological changes marked in CPL-treated EAC cells were absent when treated with MCL [ 24 , 30 ].…”